<DOC>
	<DOC>NCT01844115</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).</brief_summary>
	<brief_title>Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male or female outpatient, 1870 years of age Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for Generalized Anxiety Disorder Minimum score of 20 on Hamilton Rating Scale for Anxiety Women who are pregnant or who will be breastfeeding during the study Patients with a history of: 1. Any manic or hypomanic or mixed episode, including bipolar disorder and substanceinduced manic, hypomanic or mixed episode 2. Any depressive episode with psychotic or catatonic features 3. Panic disorder with or without agoraphobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Generalized Anxiety Disorder, GAD</keyword>
</DOC>